These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 26562685

  • 1. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Mochizuki S, Morishita H, Kobiyama K, Aoshi T, Ishii KJ, Sakurai K.
    J Control Release; 2015 Dec 28; 220(Pt A):495-502. PubMed ID: 26562685
    [Abstract] [Full Text] [Related]

  • 2. Complex Consisting of β-Glucan and Antigenic Peptides with Cleavage Site for Glutathione and Aminopeptidases Induces Potent Cytotoxic T Lymphocytes.
    Mochizuki S, Morishita H, Sakurai K.
    Bioconjug Chem; 2017 Sep 20; 28(9):2246-2253. PubMed ID: 28738674
    [Abstract] [Full Text] [Related]

  • 3. Adjuvant Activity Enhanced by Cross-Linked CpG-Oligonucleotides in β-Glucan Nanogel and Its Antitumor Effect.
    Miyamoto N, Mochizuki S, Fujii S, Yoshida K, Sakurai K.
    Bioconjug Chem; 2017 Feb 15; 28(2):565-573. PubMed ID: 27951636
    [Abstract] [Full Text] [Related]

  • 4. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity.
    Davila E, Celis E.
    J Immunol; 2000 Jul 01; 165(1):539-47. PubMed ID: 10861094
    [Abstract] [Full Text] [Related]

  • 5. Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
    Ito H, Ando T, Nakamura M, Ishida H, Kanbe A, Kobiyama K, Yamamoto T, Ishii KJ, Hara A, Seishima M, Ishikawa T.
    J Viral Hepat; 2017 Feb 01; 24(2):155-162. PubMed ID: 27807909
    [Abstract] [Full Text] [Related]

  • 6. The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.
    Tian Y, Li M, Yu C, Zhang R, Zhang X, Huang R, Lu L, Yuan F, Fan Y, Zhou B, Men K, Xu H, Yang L.
    Oncotarget; 2017 Jul 11; 8(28):45951-45964. PubMed ID: 28515346
    [Abstract] [Full Text] [Related]

  • 7. Enhanced Therapeutic Efficacy of Immunostimulatory CpG-ODN by Silencing SOCS-1 with Polysaccharide/miR-155 Complexes.
    Sumiya K, Izumi H, Sakurai K.
    ACS Appl Bio Mater; 2023 Feb 20; 6(2):774-783. PubMed ID: 36632777
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synergistic effect of dual targeting vaccine adjuvant with aminated β-glucan and CpG-oligodeoxynucleotides for both humoral and cellular immune responses.
    Jin JW, Tang SQ, Rong MZ, Zhang MQ.
    Acta Biomater; 2018 Sep 15; 78():211-223. PubMed ID: 30098441
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
    Mansourian M, Badiee A, Jalali SA, Shariat S, Yazdani M, Amin M, Jaafari MR.
    Immunol Lett; 2014 Nov 15; 162(1 Pt A):87-93. PubMed ID: 25086399
    [Abstract] [Full Text] [Related]

  • 15. Designing an immunocyte-targeting delivery system by use of beta-glucan.
    Miyamoto N, Mochizuki S, Sakurai K.
    Vaccine; 2018 Jan 02; 36(1):186-189. PubMed ID: 29174675
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and in vitro characterization of antigen-conjugated polysaccharide as a CpG DNA carrier.
    Shimada N, Ishii KJ, Takeda Y, Coban C, Torii Y, Shinkai S, Akira S, Sakurai K.
    Bioconjug Chem; 2006 Jan 02; 17(5):1136-40. PubMed ID: 16984120
    [Abstract] [Full Text] [Related]

  • 17. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.
    Karan D, Krieg AM, Lubaroff DM.
    Int J Cancer; 2007 Oct 01; 121(7):1520-8. PubMed ID: 17565748
    [Abstract] [Full Text] [Related]

  • 18. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D, Chamoto K, Zhang Y, Narita Y, Noguchi D, Ohnishi H, Iguchi T, Sakai T, Ikeda H, Nishimura T.
    Int Immunol; 2006 Mar 01; 18(3):425-34. PubMed ID: 16415100
    [Abstract] [Full Text] [Related]

  • 19. Immunostimulatory RNA is a potent inducer of antigen-specific cytotoxic and humoral immune response in vivo.
    Hamm S, Heit A, Koffler M, Huster KM, Akira S, Busch DH, Wagner H, Bauer S.
    Int Immunol; 2007 Mar 01; 19(3):297-304. PubMed ID: 17289655
    [Abstract] [Full Text] [Related]

  • 20. Encapsulation of two different TLR ligands into liposomes confer protective immunity and prevent tumor development.
    Bayyurt B, Tincer G, Almacioglu K, Alpdundar E, Gursel M, Gursel I.
    J Control Release; 2017 Feb 10; 247():134-144. PubMed ID: 28069554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.